Denali Therapeutics Inc. DNLI · Stock Open Denali Therapeutics Inc. in new tab
Denali Therapeutics Inc. Analysis (DNLI)
Is Denali Therapeutics Inc. a good investment? Denali Therapeutics Inc. (DNLI) is currently trading at 20.38 USD. Market analysts have a consensus price target of 36.06 USD. This suggests a potential upside from current levels.
Earnings Schedule: Denali Therapeutics Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.42.
Investor FAQ
Does Denali Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Denali Therapeutics Inc.?
Denali Therapeutics Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.84.
Company Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Community Discussion